What's new? Log in Free sign up

Gain Therapeutics (GANX)

Company Profile

Company profile

Ticker

GANX

Exchange

Website

www.gaintherapeutics.com

CEO

Mr. Gene Mack M.B.A.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

Flying Eagle Acquisition Corp.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

851726310

GANX stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director

The Company has received approval to begin enrollment of the Phase 1b clinical trial in Australia

Quarterly report

14 Nov 24

Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

Registration of securities for employees

Prospectus supplement for primary offering

Latest ownership filings

View all

Gwen A Melincoff

HANS PETER HASLER

DOV A MD GOLDSTEIN

Financial summary

Financial statements Chart GANX financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	12.08 mm	12.08 mm	12.08 mm	12.08 mm	12.08 mm	12.08 mm
Cash burn (monthly)	1.63 mm	(no burn)	1.49 mm	1.81 mm	2.03 mm	1.76 mm
Cash used (since last report)	8.30 mm	n/a	7.60 mm	9.24 mm	10.33 mm	8.96 mm
Cash remaining	3.78 mm	n/a	4.48 mm	2.85 mm	1.76 mm	3.13 mm
Runway (months of cash)	2.3	n/a	3.0	1.6	0.9	1.8

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

GANX institutional ownership history Ownership history

2.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	9	8	+12.5%
Opened positions	6	4	+50.0%
Closed positions	5	21	-76.2%
Increased positions	1	2	-50.0%
Reduced positions	2	1	+100.0%

13F shares	Current	Prev Q	Change
Total value	1.19 bn	1.00 bn	+18.4%
Total shares	665.71 k	820.45 k	-18.9%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Geode Capital Management	271.97 k	$484.16 mm	+48.0%
Vanguard	145.22 k	$258.49 mm	NEW
BlackRock	84.92 k	$151.17 mm	NEW
JNFC Jones Financial Companies LLLP	53.50 k	$106.47 mm	NEW
Renaissance Technologies	53.26 k	$94.81 mm	-55.1%
NTRS Northern Trust	44.94 k	$80.00 mm	NEW
Simplex Trading	4.80 k	$8.00 k	-47.0%
Creekmur Asset Management	4.44 k	$7.90 mm	NEW
WFC Wells Fargo & Company	2.65 k	$4.72 mm	NEW
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
Hohimer Wealth Management	0.00	-330.00 k	EXIT
Vanguard	145.22 k	+145.22 k	NEW
CM Management	0.00	-90.00 k	EXIT
Geode Capital Management	271.97 k	+88.24 k	+48.0%
BlackRock	84.92 k	+84.92 k	NEW
Renaissance Technologies	53.26 k	-65.44 k	-55.1%
JNFC Jones Financial Companies LLLP	53.50 k	+53.50 k	NEW
Warberg Asset Management	0.00	-51.60 k	EXIT
NTRS Northern Trust	44.94 k	+44.94 k	NEW
Virtu Financial	0.00	-27.36 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

GANX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
6 Jan 25	Gene Mack	Stock Option Common Stock	Grant	Acquire A	No	No	2.44	271,325	662.03 k	271,325
9 Aug 24	Gene Mack	Common Stock	Buy	Acquire P	No	No	1.01	14,400	14.54 k	14,400
9 Aug 24	Islam Khalid	Common Stock	Buy	Acquire P	No	No	0.9988	50,000	49.94 k	50,000
1 Jul 24	Eric I Richman	Common Stock	Buy	Acquire P	No	No	1.21	12,000	14.52 k	289,629
1 Jul 24	Eric I Richman	Common Stock	Buy	Acquire P	No	No	1.23	5,000	6.15 k	277,629
24 Jun 24	Islam Khalid	Stock Option Common Stock	Grant	Acquire A	No	No	1.29	15,000	19.35 k	15,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Roth MKM Maintains Buy on Gain Therapeutics, Maintains $7 Price Target

Roth MKM analyst Boobalan Pachaiyappan maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $7 price target.

Gain Therapeutics Initiated Phase 1b Clinical Trial Of Lead Candidate GT-02287 In People With GBA1 And Idiopathic Parkinson's Disease

The Company has received approval to begin enrollment of the Phase 1b clinical trial in AustraliaPhase 1b clinical trial will assess safety and tolerability along with biomarkers during three months of dosing with

Press releases

From Benzinga Pro

Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update

BETHESDA, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of

Gain Therapeutics To Participate in Upcoming Investor Conferences

BETHESDA, Md., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease

The Company has received approval to begin enrollment of the Phase 1b clinical trial in Australia Phase 1b clinical trial will assess safety and tolerability along with biomarkers during three months of dosing with

Gain Therapeutics To Present At Biotech Showcase 2025

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.